Clinical Complications of Iron Overload in Patients with Myelodysplastic Syndromes: a literature review

Main Article Content

Luiz Gustavo Carvalho
https://orcid.org/0000-0002-9418-0123
Andressa Hellen de Morais Batista
https://orcid.org/0000-0001-9075-4663
Isabelle Cerqueira Sousa
https://orcid.org/0000-0002-5131-3395

Abstract

Myelodysplastic Syndromes (MDS) are a group of heterogeneous hematologic disorders characterized by bone marrow involvement. Iron overload is the result of multiple transfusions and high levels of apoptosis. Based on a literature review, ferritin was identified as an important marker of iron accumulation in organs such as liver, heart and pancreas in patients with MDS. Some studies also demonstrated that iron overload caused cell cycle arrest causing apoptosis and progression to leukemia, high levels of reactive oxygen species and low levels of HIF-1a, causing apoptosis, being related to the presence of cytopenia in MDS.


 

Article Details

How to Cite
Carvalho, L. G., de Morais Batista, A. H. ., & Cerqueira Sousa, I. . (2021). Clinical Complications of Iron Overload in Patients with Myelodysplastic Syndromes: a literature review. Brazilian Journal of Case Reports, 1(2), 83–92. https://doi.org/10.52600/2763-583X.bjcr.2021.1.2.83-92
Section
Health Review
Author Biographies

Luiz Gustavo Carvalho, Universidade Federal do Ceará

Centro Universitário Christus - Unichristus, Fortaleza, CE, Brasil.

Post-Graduation Program in Translational Medicine, Federal University of Ceará, Ceará, CE, Brazil.

Andressa Hellen de Morais Batista, Centro Universitário Christus - Unichristus

Centro Universitário Christus - Unichristus, Fortaleza, CE, Brasil.  

Isabelle Cerqueira Sousa, Centro Universitário Christus - Unichristus

Centro Universitário Christus - Unichristus, Fortaleza, CE, Brasil.  

References

Oscier DG. ABC of clinical haematology: The myelodysplastic syndromes. BMJ. 1997;314(7084):883-883. doi:10.1136/bmj.314.7084.883

Gattermann N, Rachmilewitz EA. Iron overload in MDS—pathophysiology, diagnosis, and complications. Ann Hematol. 2011;90(1):1-10. doi:10.1007/s00277-010-1091-1

Racanelli AP, Falconi MA, Alves SCR, Lorand-Metze I. Alterações morfológicas no hemograma nas síndromes mielodisplásicas: sua relação com os tipos OMS e as alterações encontradas na imunofenotipagem. Journal of the Health Sciences Institute, 2014; 32(1):12-7.

Angelucci E, Cianciulli P, Finelli C, Mecucci C, Voso MT, Tura S. Unraveling the mechanisms behind iron overload and ineffective hematopoiesis in myelodysplastic syndromes. Leukemia Research. 2017;62:108-115. doi:10.1016/j.leukres.2017.10.001

Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, Bennett JM, Bowen D, Fenaux P, Dreyfus F, Kantarjian H, Kuendgen A, Levis A, Malcovati L, Cazzola M, Cermak J, Fonatsch C, Le Beau MM, Slovak ML, Krieger O, Luebbert M, Maciejewski J, Magalhaes SMM, Miyazaki Y, Pfeilstöcker M, Sekeres M, Sperr WR, Stauder R, Tauro S, Valent P, Vallespi T, van de Loosdrecht AA, Germing U, Haase D. Revised International Prognostic Scoring System for Myelodysplastic Syndromes. Blood. 2012;120(12):2454-2465. doi:10.1182/blood-2012-03-420489

Shenoy N, Vallumsetla N, Rachmilewitz E, Verma A, Ginzburg Y. Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome. Blood. 2014;124(6):873-881. doi:10.1182/blood-2014-03-563221

On behalf of the IRON-2 Study Group, Remacha ÁF, Arrizabalaga B, Villegas A, Durán MS, Hermosín L, de Paz R, Garcia M, Campelo MD, Sanz G. Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications. Ann Hematol. 2015;94(5):779-787. doi:10.1007/s00277-014-2274-y

Gattermann N. Iron overload in myelodysplastic syndromes (MDS). Int J Hematol. 2018;107(1):55-63. doi:10.1007/s12185-017-2367-1

Ko B-S, Chang C-S, Chang M-C, Chen TY, Chiou T-J, Chiu C-F, Huang W-L, Kao W-Y, Lan Y-J, Lin S-F, Tan T-D, Tang J-L, Tzeng C-H, Wang P-N, Yet S-P, Tien H-F. Guidelines for treating iron overload in myelodysplastic syndromes: a Taiwan consensus statement. Int J Hematol. 2014;100(1):7-15. doi:10.1007/s12185-014-1607-x

Shammo JM, Komrokji RS. Clinical consequences of iron overload in patients with myelodysplastic syndromes: the case for iron chelation therapy. Expert Review of Hematology. 2018;11(7):577-586. doi:10.1080/17474086.2018.1486188

Du Y, Long Z, Chen M, Han B, Hou B, Feng F. Observational Monitoring of Patients with Aplastic Anemia and Low/Intermediate-1 Risk of Myelodysplastic Syndromes Complicated with Iron Overload. Acta Haematol. 2017;138(2):119-128. doi:10.1159/000479422

Zheng Q, Zhao Y, Guo J, Zhao S, Song L, Fei C, Zhang Z, Li X, Chang C. Iron overload promotes erythroid apoptosis through regulating HIF-1a/ROS signaling pathway in patients with myelodysplastic syndrome. Leukemia Research. 2017;58:55-62. doi:10.1016/j.leukres.2017.04.005

Hua Y, Wang C, Jiang H, Wang Y, Liu C, Li L, Liu H, Shao Z, Fu R. Iron overload may promote alteration of NK cells and hematopoietic stem/progenitor cells by JNK and P38 pathway in myelodysplastic syndromes. Int J Hematol. 2017;106(2):248-257. doi:10.1007/s12185-017-2237-x

Peng H, Wen J, Zhang L, Li H, Chang C-C, Zu Y, Zhou X. A systematic modeling study on the pathogenic role of p38 MAPK activation in myelodysplastic syndromes. Mol BioSyst. 2012;8(4):1366. doi:10.1039/c2mb05184b

Meng X, Zhang J, Yin L, Pu Y. Involvement of hypoxia-inducible factor-1 α (HIF-1α) in inhibition of benzene on mouse hematopoietic system. Journal of Toxicology and Environmental Health, Part A. 2016;79(9-10):402-406. doi:10.1080/15287394.2016.1176616

De Souza GF, Ribeiro HL, De Sousa JC, Heredia FF, De Freitas RM, Martins MRA, Goncalves RP, Pinheiro RF, Magalhaes SMM. HFE gene mutation and oxidative damage biomarkers in patients with myelodysplastic syndromes and its relation to transfusional iron overload: an observational cross-sectional study. BMJ Open. 2015;5(4):e006048-e006048. doi:10.1136/bmjopen-2014-006048

Pagano L, Caira M. Risks for infection in patients with myelodysplasia and acute leukemia. Current Opinion in Infectious Diseases. 2012;25(6):612-618. doi:10.1097/QCO.0b013e328358b000

Gu S, Song X, Zhao Y, Guo J, Fei C, Xu F, Wu L, Zhang X, Zhao J, Chang C, Li X. The Evaluation of iron overload through hepcidin level and its related factors in myelodysplastic syndromes. Hematology. 2013;18(5):286-294. doi:10.1179/1607845412Y.0000000064

Leitch HA, Parmar A, Wells RA, Chodirker L, Zhu N, Nevill TJ, Yee KWL, Leber B, Keating M-M, Sabloff M, St. Hilaire E, Kumar R, Delage R, Geddes M, Storring JM, Kew A, Shamy A, Elemary M, Lenis M, Mamedov A, Ivo J, Francis J, Zhang L, Buckstein R. Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis. Br J Haematol. 2017;179(1):83-97. doi:10.1111/bjh.14825

Angelucci E, Santini V, Di Tucci AA, Quaresmini G, Finelli C, Volpe A, Quarta G, Rivellini F, Sanpaolo G, Cilloni D, Salvi F, Caocci G, Molteni A, Vallisa D, Voso MT, Fenu S, Borin L, Latte G, Alimena G, Storti S, Piciocchi A, Fazi P, Vignetti M, Tura S. Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial). Eur J Haematol. 2014;92(6):527-536. doi:10.1111/ejh.12300

Zeidan AM, Griffiths EA. To chelate or not to chelate in MDS: That is the question! Blood Reviews. 2018;32(5):368-377. doi:10.1016/j.blre.2018.03.002

Most read articles by the same author(s)